Cart
sales@molnova.com
Lorcaserin
CAS No. 616202-92-7
Lorcaserin( Lorcaserin | Belviq | Belvig | HSDB 8128 )
Catalog No. M15327 CAS No. 616202-92-7
Lorcaserin(APD356) is a selective full agonist of human 5-HT2C receptor with Ki of 15 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLorcaserin
-
NoteResearch use only, not for human use.
-
Brief DescriptionLorcaserin(APD356) is a selective full agonist of human 5-HT2C receptor with Ki of 15 nM.
-
DescriptionLorcaserin(APD356) is a selective full agonist of human 5-HT2C receptor with Ki of 15 nM.
-
In Vitro——
-
In Vivo——
-
SynonymsLorcaserin | Belviq | Belvig | HSDB 8128
-
PathwayEndocrinology/Hormones
-
Target5-HT Receptor
-
Recptor5-HT2C
-
Research AreaMetabolic Disease
-
Indication——
Chemical Information
-
CAS Number616202-92-7
-
Formula Weight195.69
-
Molecular FormulaC11H14ClN
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESC[C@H]1CNCCC2=CC=C(Cl)C=C12
-
Chemical Name(R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Chan EW, et al. Obes Rev. 2013 Jan 2
molnova catalog
related products
-
CART (62-76) (rat, h...
Cocaine- and amphetamine-regulated transcript (CART) peptide fragment that inhibits food intake. Attenuates NPY-induced feeding and decreases food intake in food-restricted goldfish, and induces anxiogenic-like effects in elevated plus-maze test in rats. Modulates the activity of striatal noradrenergic, and corticostrial and hypothalamic serotoninergic systems, with no major effect on dopaminergic pathways in rat brain.
-
Dapoxetine HCl
Dapoxetine HCl is a selectivity short-acting serotonin reuptake inhibitor used for the therapy of premature ejaculation.
-
Elbasvir
Elbasvir is an inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection.
